首页> 美国卫生研究院文献>Journal of Medical Devices >Development and Validation of Endovascular Chemotherapy Filter Device for Removing High-Dose Doxorubicin: Preclinical Study
【2h】

Development and Validation of Endovascular Chemotherapy Filter Device for Removing High-Dose Doxorubicin: Preclinical Study

机译:去除大剂量阿霉素的血管内化疗过滤器装置的开发和验证:临床前研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To develop a novel endovascular chemotherapy filter (CF) able to remove excess drug from the blood during intra-arterial chemotherapy delivery (IAC), thus preventing systemic toxicities and thereby enabling higher dose IAC. A flow circuit containing 2.5 mL of ion-exchange resin was constructed. Phosphate-buffered saline (PBS) containing 50 mg doxorubicin (Dox) was placed in the flow model with the hypothesis that doxorubicin would bind rapidly to resin. To simulate IAC, 50 mg of doxorubicin was infused over 10 min into the flow model containing resin. Similar testing was repeated with porcine serum. Doxorubicin concentrations were measured over 60 min and compared to controls (without resin). Single-pass experiments were also performed. Based on these experiments, an 18F CF was constructed with resin in its tip. In a pilot porcine study, the device was deployed under fluoroscopy. A control hepatic doxorubicin IAC model (no CF placed) was developed in another animal. A second CF device was created with a resin membrane and tested in the infrarenal inferior vena cava (IVC) of a swine. In the PBS model, resin bound 76% of doxorubicin in 10 min, and 92% in 30 min (P  <  0.001). During IAC simulation, 64% of doxorubicin bound in 10 min and 96% in 60 min (P  <  0.001). On average, 51% of doxorubicin concentration was reduced during each pass in single pass studies. In porcine serum, 52% of doxorubicin bound in 10 min, and 80% in 30 min (P  <  0.05). CF device placement and administration of IAC were successful in three animals. No clot was present on the resin within the CF following the in vivo study. The infrarenal IVC swine study demonstrated promising results with up to 85% reduction in peak concentration by the CF device. An endovascular CF device was developed and shown feasible in vitro. An in vivo model was established with promising results supporting high-capacity rapid doxorubicin filtration from the blood that can be further evaluated in future studies.
机译:为了开发一种新型的血管内化疗过滤器(CF),该过滤器能够在动脉内化疗递送(IAC)过程中从血液中去除多余的药物,从而防止全身毒性,从而实现更高剂量的IAC。构造了一个包含2.5?mL离子交换树脂的流路。将含有50μmg阿霉素(Dox)的磷酸盐缓冲盐水(PBS)置于流动模型中,并假设阿霉素会迅速与树脂结合。为了模拟IAC,在10分钟内将50 µmg的阿霉素注入含有树脂的流动模型中。用猪血清重复类似的测试。在60分钟内测量阿霉素浓度,并与对照(不含树脂)进行比较。还进行了单遍实验。根据这些实验,用树脂制成的18F CF尖端。在一项初步的猪研究中,该设备在荧光检查下展开。在另一只动物中建立了对照肝阿霉素IAC模型(未放置CF)。用树脂膜制成第二个CF装置,并在猪的肾下腔静脉(IVC)中进行测试。在PBS模型中,树脂在10分钟内结合了76%的阿霉素,在30分钟内结合了92%的阿霉素(P <0.001)。在IAC模拟过程中,阿霉素的10分钟结合率为64%,而60分钟的结合率为96%(P <0.001)。在单次通过研究中,平均每次通过过程中阿霉素浓度降低51%。在猪血清中,阿霉素在10分钟中结合了52%,在30分钟中结合了80%(P <0.05)。 CF设备的放置和IAC的施用在三只动物中均获得成功。体内研究后,CF内的树脂上不存在凝块。肾下IVC猪研究显示出令人鼓舞的结果,CF设备将峰值浓度降低了85%。开发了一种血管内CF装置,并在体外显示可行。建立了体内模型,该模型具有可观的结果,可支持从血液中进行大容量快速阿霉素的快速过滤,该模型可在未来的研究中进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号